JP2023166402A5 - - Google Patents

Download PDF

Info

Publication number
JP2023166402A5
JP2023166402A5 JP2023131429A JP2023131429A JP2023166402A5 JP 2023166402 A5 JP2023166402 A5 JP 2023166402A5 JP 2023131429 A JP2023131429 A JP 2023131429A JP 2023131429 A JP2023131429 A JP 2023131429A JP 2023166402 A5 JP2023166402 A5 JP 2023166402A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023131429A
Other languages
English (en)
Japanese (ja)
Other versions
JP7854419B2 (ja
JP2023166402A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/028987 external-priority patent/WO2019209995A2/en
Application filed filed Critical
Publication of JP2023166402A publication Critical patent/JP2023166402A/ja
Publication of JP2023166402A5 publication Critical patent/JP2023166402A5/ja
Application granted granted Critical
Publication of JP7854419B2 publication Critical patent/JP7854419B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023131429A 2018-04-25 2023-08-10 最適化された抗tl1a抗体 Active JP7854419B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862662605P 2018-04-25 2018-04-25
US62/662,605 2018-04-25
US201862756494P 2018-11-06 2018-11-06
US62/756,494 2018-11-06
PCT/US2019/028987 WO2019209995A2 (en) 2018-04-25 2019-04-24 Optimized anti-tl1a antibodies
JP2020560230A JP7332627B2 (ja) 2018-04-25 2019-04-24 最適化された抗tl1a抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020560230A Division JP7332627B2 (ja) 2018-04-25 2019-04-24 最適化された抗tl1a抗体

Publications (3)

Publication Number Publication Date
JP2023166402A JP2023166402A (ja) 2023-11-21
JP2023166402A5 true JP2023166402A5 (https=) 2024-01-05
JP7854419B2 JP7854419B2 (ja) 2026-05-01

Family

ID=68295788

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560230A Active JP7332627B2 (ja) 2018-04-25 2019-04-24 最適化された抗tl1a抗体
JP2023131429A Active JP7854419B2 (ja) 2018-04-25 2023-08-10 最適化された抗tl1a抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020560230A Active JP7332627B2 (ja) 2018-04-25 2019-04-24 最適化された抗tl1a抗体

Country Status (10)

Country Link
US (5) US20210070871A1 (https=)
EP (1) EP3784699A4 (https=)
JP (2) JP7332627B2 (https=)
KR (2) KR20250024101A (https=)
CN (2) CN112585165B8 (https=)
AU (2) AU2019261426A1 (https=)
CA (1) CA3098374A1 (https=)
MA (1) MA52366A (https=)
TW (2) TWI842707B (https=)
WO (1) WO2019209995A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101982899B1 (ko) 2011-09-30 2019-05-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 TL1a에 대한 항체 및 그의 용도
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
KR20190082815A (ko) * 2016-10-26 2019-07-10 세다르스-신나이 메디칼 센터 중화 항-tl1a 단일 클론 항체
CN112585165B8 (zh) 2018-04-25 2025-02-14 普罗米修斯生物科学公司 优化的抗tl1a抗体
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
NZ787680A (en) * 2019-10-24 2026-02-27 Cedars Sinai Medical Center Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
TW202600603A (zh) * 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
BR112022022020A2 (pt) * 2020-04-29 2023-01-31 Chia Tai Tianqing Pharmaceutical Group Co Ltd Proteína bifuncional contra pd-1 e tgf-ss
BR112022025667A2 (pt) * 2020-06-26 2023-03-07 Pfizer Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a
AU2021377688A1 (en) * 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
MX2023009681A (es) * 2021-02-18 2023-10-30 Prometheus Biosciences Inc Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon.
TW202246322A (zh) * 2021-02-18 2022-12-01 美商普羅米修斯生物科學股份有限公司 包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途
CN119604535A (zh) * 2022-08-19 2025-03-11 四川科伦博泰生物医药股份有限公司 Ptk7结合蛋白及其用途
AU2024273758A1 (en) 2023-05-17 2025-12-04 Genentech, Inc. Anti-tl1a antibody therapeutic methods
CN119306830B (zh) * 2023-07-11 2025-06-20 东莞市朋志生物科技有限公司 抗皮质醇抗体、检测皮质醇的试剂和试剂盒
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
US20250109209A1 (en) 2023-10-03 2025-04-03 Absci Corporation Tl1a associated antibody compositions and methods of use
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
CN120530139A (zh) * 2023-12-29 2025-08-22 成都优洛生物科技有限公司 抗tl1a抗体或其抗原结合片段及应用
US12319742B1 (en) 2024-01-24 2025-06-03 Shattuck Labs, Inc. Antibodies that bind TNFRSF25
JP2025115976A (ja) 2024-01-26 2025-08-07 フューチャージェン・バイオファーマシューティカル(ベイジン)カンパニー・リミテッド Tl1aに特異的に結合できる抗体及びその使用
CN120424214A (zh) * 2024-02-05 2025-08-05 三生国健药业(上海)股份有限公司 一种抗tl1a抗体及其制备方法和用途
US20250376530A1 (en) 2024-05-17 2025-12-11 Genentech, Inc. Methods for treatment of inflammatory bowel disease with an anti-tl1a antibody
WO2026056853A1 (zh) * 2024-09-10 2026-03-19 先声药业有限公司 Tl1a抗体及其应用
WO2026072993A1 (en) 2024-09-27 2026-04-02 Genentech, Inc. Methods for treatment of metabolic dysfunction-associated steatohepatitis with an anti-tl1a antibody
WO2026072983A1 (en) 2024-09-27 2026-04-02 Genentech, Inc. Methods for treatment of atopic dermatitis with an anti-tl1a antibody

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
JP4046349B2 (ja) 1994-11-07 2008-02-13 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 腫瘍壊死因子−γ
US6599719B2 (en) 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
US6824767B2 (en) 1994-11-07 2004-11-30 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US20030198640A1 (en) 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US20030129189A1 (en) 1994-11-07 2003-07-10 Guo-Liang Yu Tumor necrosis factor-gamma
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
JP2002508940A (ja) 1998-03-13 2002-03-26 デイナ−ファーバー キャンサー インスティチュート,インコーポレイテッド ヒト化抗体およびその使用
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU5124500A (en) 1999-04-30 2000-11-17 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US6571638B2 (en) 2000-06-30 2003-06-03 Sawtek, Inc. Surface-acoustic-wave pressure sensor and associated methods
AU2001277857A1 (en) 2000-07-07 2002-01-21 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6824989B1 (en) 2000-09-01 2004-11-30 Upstate Biotechnology, Inc. Recombinant monoclonal antibody to phosphotyrosine-containing proteins
CA2391711A1 (en) 2001-06-26 2002-12-26 University Of Guelph Non-radioactive assay of lipopolysaccharide kinases
WO2003068821A2 (en) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2004035537A2 (en) 2002-10-16 2004-04-29 Euro-Celtique S.A. Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
EP1567555A4 (en) 2002-11-27 2006-06-21 Biogen Idec Inc HUMANIZED ANTIBODIES AGAINST CHEMOTOXIC MONOCYTE PROTEINS
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20050101889A1 (en) 2003-11-06 2005-05-12 Freeman Gary A. Using chest velocity to process physiological signals to remove chest compression artifacts
CA2573293A1 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
KR100596277B1 (ko) 2004-08-20 2006-07-03 동부일렉트로닉스 주식회사 반도체 소자 및 그의 절연막 형성 방법
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
KR101443050B1 (ko) 2005-05-06 2014-09-22 지모제넥틱스, 인코포레이티드 Il-31 단클론성 항체 및 사용법
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
US20090317388A1 (en) 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
CN103145842A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006284922B2 (en) 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US9896511B2 (en) * 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
WO2008106579A2 (en) 2007-02-28 2008-09-04 Cedars-Sinai Medical Center The role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
UA104132C2 (en) 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a
CN101469270B (zh) 2007-12-27 2012-08-22 牛斌 工业连续化塑料裂解器
EP2238154B1 (en) 2008-01-18 2015-09-16 Bio-Rad Laboratories, Inc. Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography
NZ591484A (en) 2008-09-29 2012-09-28 Roche Glycart Ag Antibodies against human il 17 and uses thereof
WO2010111180A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
SG10201502330TA (en) 2009-08-03 2015-05-28 Univ Miami Method for in vivo expansion of t regulatory cells
WO2011106707A2 (en) 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
KR101603001B1 (ko) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
KR101871008B1 (ko) 2010-09-16 2018-06-25 발리오팜 아게 항-huTNFR1 항체
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
US9902996B2 (en) 2011-02-11 2018-02-27 Cedars-Sinai Medical Center Methods of predicting the need for surgery in crohn's disease
WO2012161856A1 (en) 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
CN103732623B (zh) 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
TWI687439B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
KR101982899B1 (ko) 2011-09-30 2019-05-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 TL1a에 대한 항체 및 그의 용도
KR20230143201A (ko) 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체(캐리어)를 포함하는 의약
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
PL2880170T3 (pl) 2012-08-02 2017-02-28 F.Hoffmann-La Roche Ag SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA
KR20150037959A (ko) 2012-08-02 2015-04-08 에프. 호프만-라 로슈 아게 단량체 및 다량체 분자의 제조 방법 및 이의 용도
JPWO2014051109A1 (ja) * 2012-09-28 2016-08-25 協和発酵キリン株式会社 抗ヒトbmp9抗体および該抗体を有効成分とする異所性骨化疾患の治療剤
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
WO2014106602A1 (en) 2013-01-02 2014-07-10 Glenmark Pharmaceuticals S.A. Antibodies that bind to tl1a and their uses
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
US20140377253A1 (en) 2013-03-15 2014-12-25 Abbvie Biotherapeutics Inc. Fc variants
SG11201509982UA (https=) * 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
US9683998B2 (en) 2013-11-13 2017-06-20 Pfizer Inc. Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
ES2811274T3 (es) * 2014-04-18 2021-03-11 Univ Leland Stanford Junior Anticuerpos monoclonales humanizados y quiméricos para CD99
EP3137063A4 (en) 2014-05-02 2017-12-13 Teva Pharmaceutical Industries Ltd. Treatment of crohn's disease with delayed-release 6-mercaptopurine
ES2936810T3 (es) 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
US10160805B2 (en) 2014-07-11 2018-12-25 New York University Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody
EP3224275B1 (en) 2014-11-14 2020-03-04 F.Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
EP3973980A1 (en) 2015-03-31 2022-03-30 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
EP3280439A1 (en) * 2015-04-07 2018-02-14 INSERM - Institut National de la Santé et de la Recherche Médicale Anti-pd-l1 immunotoxin for use in therapy
US10647756B2 (en) 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies
CA2998174A1 (en) 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US10526413B2 (en) 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40
US20180319889A1 (en) 2015-11-02 2018-11-08 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
ITUB20155097A1 (it) * 2015-11-05 2017-05-05 Biouniversa Srl Anticorpi umanizzati anti-BAG3
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CA2965652A1 (en) 2016-04-29 2017-10-29 Pfizer Inc. Interferon beta antibodies
MX392069B (es) 2016-05-09 2025-03-21 Bristol Myers Squibb Co Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
CA3031028C (en) 2016-07-25 2024-02-13 Lu Wang Affinity chromatography wash buffer
KR20190082815A (ko) 2016-10-26 2019-07-10 세다르스-신나이 메디칼 센터 중화 항-tl1a 단일 클론 항체
CN110430801B (zh) 2016-12-14 2024-04-30 比奥拉治疗股份有限公司 使用tnf抑制剂治疗胃肠道疾病
BR112020007002A2 (pt) 2017-10-10 2020-11-17 Sanofi anticorpos anti-cd38 e métodos de uso
EP3728316B1 (en) 2017-12-19 2025-02-26 invoX Pharma Limited Fc binding fragments comprising a pd-l1 antigen-binding site
CN112585165B8 (zh) 2018-04-25 2025-02-14 普罗米修斯生物科学公司 优化的抗tl1a抗体
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
PT3820569T (pt) 2018-07-12 2025-01-14 Invox Pharma Ltd Moléculas de anticorpo que se ligam a pd-l1 e cd137
ES3044118T3 (en) 2018-07-12 2025-11-26 Invox Pharma Ltd Antibody molecules that bind cd137 and ox40
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
JP7462621B2 (ja) 2018-10-09 2024-04-05 サノフイ 三重特異性抗cd38、抗cd28、および抗cd3結合タンパク質ならびにウイルス感染を処置するための使用方法
SG11202104136YA (en) 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins
NZ787680A (en) 2019-10-24 2026-02-27 Cedars Sinai Medical Center Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
BR112022025667A2 (pt) 2020-06-26 2023-03-07 Pfizer Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a

Similar Documents

Publication Publication Date Title
JP2023171775A5 (https=)
JP2022184985A5 (https=)
JP2023103258A5 (https=)
JP2023166402A5 (https=)
JP2021184963A5 (https=)
JP2024116190A5 (https=)
JP2023145572A5 (https=)
JP2023518821A5 (https=)
JP2025511899A5 (https=)
JP2022068302A5 (https=)
JP2025176106A5 (https=)
JP2022543046A5 (https=)
JP2022541332A5 (https=)
JP2023514727A5 (https=)
JP2023181322A5 (https=)
JP2022538797A5 (https=)
JP2023552816A5 (https=)
JP2023022224A5 (https=)
JP2024045126A5 (https=)
JP2025098156A5 (https=)
JP2023093656A5 (https=)
JP2023078173A5 (https=)
JP2025094038A5 (https=)
JP2025090801A5 (https=)
JP2024149687A5 (https=)